Evidence map›Paper›PMID 34973412›Full record

ReviewTrends in cardiovascular medicine2023

Frontiers of cardiovascular polypills: From atherosclerosis and beyond.

Sonali R Gnanenthiran, Anubha Agarwal, Anushka Patel

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06029712 (Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06029712 phase2completednot on this mapstarted 2024, after this paper: background citation

Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2024 to 2025Enrolled35ConditionsHeart Failure With Reduced Ejection Fraction, HIV InfectionsArmsHeart failure polypill, Control Rx
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
  2. Fixed Combination for the Treatment of Dyslipidaemia.Current atherosclerosis reports · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Sonali R GnanenthiranThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: sgnanenthiran@georgeinstitute.org.au.
Anubha AgarwalThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.
Anushka PatelThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.

Funding

Heart Failure Polypill in India: A Late-Stage Implementation StrategyK99HL157687 · NHLBI · WASHINGTON UNIVERSITY · PI AGARWAL, ANUBHA · 2022 to 2023
$351k
NHLBI NIH HHS K99 HL157687
6 · The paper itself

Abstract

Fixed-dose combination (FDC) therapies (also known as polypills) remain underutilized in clinical practice despite over two decades of evidence from randomized controlled trials demonstrating increased adherence to multidrug therapy, improved cardiovascular disease (CVD) risk factor control, and lower incidence of cardiovascular events. Evidence demonstrates that FDC-based implementation strategies can substantially complement and augment current strategies for CVD risk prevention globally. The next decade is likely to extend the frontier of cardiovascular FDC therapies, particularly given expected advances in FDC manufacturing technology and accessibility. FDC-based anti-hypertensive therapies are emerging as integral components of a pragmatic blood pressure lowering strategy. Cardiovascular FDCs are rapidly approaching its coming of age, transforming from heavily hyped research tools to pragmatic clinical instruments. This review evaluates the current evidence for cardiovascular FDCs, barriers to current use, and potential next generation advances.

Indexed as

AtherosclerosisCardiovascular DiseasesAntihypertensive AgentsDrug CombinationsDrug Therapy, CombinationHumansLeprostatic AgentsPlatelet Aggregation InhibitorsAntihypertensive AgentsDrug CombinationsLeprostatic AgentsPlatelet Aggregation InhibitorsAtherosclerosisCardiovascular diseaseFixed dose combinationHypertensionPolypillPrevention

Identifiers

PMID34973412
PMCPMC10424636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.